Biolidics calls for trade halt pending reimbursements for cancer tests

The fees related to the tests will be reimbursed by China’s National Healthcare Security Administration under its national basic medical insurance programme.

Medtech firm Biolidics has called for a trading halt pending a revised statement with clarifications on the reimbursements it is set to receive for cancer laboratory-developed tests (LDTs) in China, an announcement on the Singapore Exchange (SGX) revealed.

The Catalist-listed firm, which specialises in cancer diagnostic solutions, had earlier announced that the fees related to the LDTs offered to its laboratory partner, Hunan Agen Medicine Laboratory Technology Co., will be reimbursed by China’s National Healthcare Security Administration under its national basic medical insurance programme.

However, Biolidics clarified that the reimbursements will be for the cancer drug treatments, not the tests, and that such reimbursements have yet to be confirmed.

“The company wishes to clarify that Hunan Agen Lab will be providing the LDT to Hunan Cancer Hospital, which has obtained approval to commence clinical trials for the programmed death-ligand1 (PD-L1) in the administration of drug treatments,” Biolidics’ CEO and executive director Lew Kwang Ping said.

The clinical trials serve to improve patient selection to the targeted cancer drug treatment, as well as to show the efficacy of the combination treatment and changes in circulating tumour cells (CTCs) after drug administration.

Using a small amount of blood sample, the LDTs offered by Hunan Agen Lab have the potential for many applications throughout the various stages of a patient's cancer journey, such as cancer screening, cancer staging and post-cancer monitoring. The LDTs that utilises Biolidics’ technology subject cancer patients to minimal invasive procedures, improve clinical outcomes, and optimise cost and efficiency.

“Successful clinical trials could lead to the potential reimbursement of such cancer drug treatments by the National Healthcare Security Administration,” Lew noted.

The people you want to reach are already in this room.

Every quarter, SBR lands on the desks of the founders, CFOs, and directors running Asia's most consequential companies. Every day, they open our newsletter and read our website. It's a room that took twenty years to build — and it's the one most of our partners are trying to get into.

The good news is that the door is open. We work with companies on thought leadership articles, sponsored content, industry summits across Southeast Asia, regional awards programmes, podcasts, and media placements in print and digital. The shape of the right partnership depends on what you're trying to do, which is why we'd rather start with a conversation than send a rate card.

If you have something this room should know about, tell us. We'll tell you honestly whether we can help, and how.

No rate cards until we understand the brief. It's a better use of everyone's time.

Book a meeting

| Or download the media kit (PDF)

240,000 senior readers quarterly in print Top 1,700 Singapore companies reached

7 markets across Southeast Asia